Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-A-1041 tablet formulation bioavailability and food effect study in healthy volunteers
NCT07051993Phase 1Completed
- Sponsor
- Genentech
- Start
- Jun 2025
- Primary completion
- Jul 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ZN-A-1041, sponsored by Genentech. Primary endpoints: Maximum Observed Concentration, Area Under the Concentration-Time Curve from Hour 0 to the Last Measurable Concentration and 4 more. Started Jun 2025; status: completed.
02
Drugs
ZN-A-1041
Beyond the preview
Go deeper on NCT07051993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07051993.